To this end, our observations in the present study indicate that a rationale-based regimen combining these inhibitors (e.g., MI-3) and HDAC inhibitors (e.g., chidamide) might display significantly increased anti-tumor activity towards AML carrying MLL-rearrangement, compared to each single agent, at least in the preclinical setting. The gene discussed is HDAC9; the disease is neoplasm.